The ISC Board has made class 12th syllabus available for the academic year 2026-27. In this article we have explained the ...
Investor's Business Daily on MSN
Why this biotech, up 12% since its breakout, yo-yoed on a key FDA development
Pharvaris stock jumped early Monday, but closed down, after the FDA agreed to review the company's treatment for a serious ...
Highly sensitive next-generation sequencing-based MRD testing will identify eligible patients with T-cell malignancies ...
SkinTE® would be the first new biologic commercially available in the U.S. for the treatment of a common chronic wound indication in nearly 30 years, if approved. SkinTE® is a first-in-class ...
Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of ...
No dose-limiting toxicities, serious adverse events, ICANS, or deaths were reported; infusion-related reactions and CRS were Grade 1–2, and none required glucocorticoids for CRS management Additional ...
Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 study No dose-limiting toxicities, serious adverse ...
LABT READ THE FULL LABT RESEARCH REPORT We are initiating coverage of Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT) with a valuation of $12.00. Lakewood-Amedex is a clinical-stage ...
Deadline to register is July 21. For more details, visit The IC3 Movement’s 10th Annual Conference and Expo 2026 will be on ...
Traders appeared particularly focused on companies advancing toward late-stage clinical development, securing new regulatory clearances, or gaining broader visibility through public market events.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results